TY - JOUR
T1 - Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy
T2 - real-life experience
AU - Segman, Yafit
AU - Ribakovsky, Elena
AU - Avigdor, Abraham
AU - Goldhecht, Yair
AU - Vainstein, Vladimir
AU - Goldschmidt, Neta
AU - Harlev, Shimrit
AU - Horwitz, Netanel
AU - Gutwein, Odit
AU - Gurion, Ronit
AU - Itchaki, Gilad
AU - Abadi, Uri
AU - Nemets, Anatoly
AU - Sofer, Orit
AU - Zektser, Miri
AU - Tadmor, Tamar
AU - Dally, Nagib
AU - Filanovsky, Kalman
AU - Leiba, Merav
AU - Sarid, Nadav
AU - Benyamini, Noam
AU - Herishanu, Yair
AU - Ram, Ron
AU - Perry, Chava
AU - Avivi, Irit
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.
AB - The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.
KW - Lymphoma and Hodgkin disease
KW - immunotherapeutic approaches
KW - relapsed refractory DLBCL
UR - http://www.scopus.com/inward/record.url?scp=85091609469&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1824069
DO - 10.1080/10428194.2020.1824069
M3 - Article
C2 - 32981410
AN - SCOPUS:85091609469
SN - 1042-8194
VL - 62
SP - 118
EP - 124
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -